Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 6 clinical trials
None
High-Dose Chemotherapy Given Together With Peripheral Blood Stem Cell Transplant in Treating Patients With Intestinal T-Cell Lymphoma

transplant in treating patients with intestinal T-cell lymphoma.

prednisolone
etoposide
t-cell lymphoma
cell transplantation
vincristine
  • 36 views
  • 07 Nov, 2020
  • 1 location
None
CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1.

It has been recently reported that EATL type 1, but not refractory coeliac disease, strongly expressed CD30 and might benefit from brentuximab vedotin. Since the safety profile of the combination brentuximab vedotin and CHP is known and since the role of etoposide as part of induction regimen is not demonstrated, …

  • 0 views
  • 18 Feb, 2021
  • 1 location
None
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone in treating patients with peripheral T-cell lymphoma. Duvelisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such …

etoposide
gilbert's syndrome
experimental drug
corticosteroids
platelet count
  • 0 views
  • 19 Jan, 2022
  • 7 locations
None
Study of Lacutamab in Peripheral T-cell Lymphoma

), Monomorphic epitheliotropic intestinal T cell lymphoma (MEITL), NK-T cell lymphoma (NKT) and Aggressive NK-cell leukemia (ANKL). The design is non comparative meaning that non comparison between arms

measurable disease
angioimmunoblastic t-cell lymphoma
t-cell leukemia
ct scan
peripheral t-cell lymphoma
  • 0 views
  • 15 Dec, 2021
  • 37 locations
None
CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label Study

Phase I was a single arm, open label, dose increasing study to explore the safety, tolerance and Cytodynamic characteristics of the drug, and to preliminarily observe the efficacy of the study drug in relapsed / refractory CD7 Positive hematolymph system malignant tumor patients, so as to explore the clinical applicable …

  • 0 views
  • 27 Jan, 2021
  • 1 location
None
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas

This phase I/II trial studies the side effects and best dose of pralatrexate when given together with pembrolizumab and how well they work in treating patients with peripheral T-cell lymphomas that has come back after a period of improvement or has not responded to treatment. Pralatrexate may stop the growth …

t-cell lymphoma
large cell lymphoma
direct bilirubin
ct scan
monoclonal protein
  • 3 views
  • 20 Aug, 2021
  • 3 locations